These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 29395184)

  • 1. Management of Hypertension and High Low-Density Lipoprotein in Pediatric Type 1 Diabetes.
    Katz ML; Guo Z; Laffel LM
    J Pediatr; 2018 Jun; 197():140-146.e12. PubMed ID: 29395184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is global cardiovascular risk considered in current practice? Treatment and control of hypertension, hyperlipidemia, and diabetes according to patients' risk level.
    Roccatagliata D; Avanzini F; Monesi L; Caimi V; Lauri D; Longoni P; Marchioli R; Tombesi M; Tognoni G; Roncaglioni MC;
    Vasc Health Risk Manag; 2006; 2(4):507-14. PubMed ID: 17323606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in utilization of lipid- and blood pressure-lowering agents and goal attainment among the U.S. diabetic population, 1999-2008.
    Kuznik A; Mardekian J
    Cardiovasc Diabetol; 2011 Apr; 10():31. PubMed ID: 21496321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihypertensive prescribing practices: impact of the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
    Player MS; Gill JM; Fagan HB; Mainous AG
    J Clin Hypertens (Greenwich); 2006 Dec; 8(12):860-4. PubMed ID: 17170611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial.
    Ikramuddin S; Korner J; Lee WJ; Connett JE; Inabnet WB; Billington CJ; Thomas AJ; Leslie DB; Chong K; Jeffery RW; Ahmed L; Vella A; Chuang LM; Bessler M; Sarr MG; Swain JM; Laqua P; Jensen MD; Bantle JP
    JAMA; 2013 Jun; 309(21):2240-9. PubMed ID: 23736733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension.
    Lan J; Zhao Y; Dong F; Yan Z; Zheng W; Fan J; Sun G
    J Ethnopharmacol; 2015 Feb; 161():69-81. PubMed ID: 25498346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug management for hypertension in type 2 diabetes in family practice.
    Putnam W; Buhariwalla F; Lacey K; Goodfellow M; Goodine RA; Hall J; Macdonald I; Murray M; Smith P; Burge F; Natarajan N; Lawson B
    Can Fam Physician; 2009 Jul; 55(7):728-34. PubMed ID: 19602663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological treatment of hypertension and hyperlipidemia in Izhevsk, Russia.
    Cybulsky M; Cook S; Kontsevaya AV; Vasiljev M; Leon DA
    BMC Cardiovasc Disord; 2016 Jun; 16():122. PubMed ID: 27255373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Self-reported insulin pump prescribing practices in pediatric type 1 diabetes.
    Fredette ME; Zonfrillo MR; Park S; Quintos JB; Gruppuso PA; Topor LS
    Pediatr Diabetes; 2021 Aug; 22(5):758-765. PubMed ID: 33855806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. General practitioners' prescribing of lipid-lowering medications for Indigenous and non-Indigenous Australians, 2001-2013.
    Trivedi AN; Pollack AJ; Britt HC; Miller GC; Harrison C; Kelaher MA
    Med J Aust; 2015 Nov; 203(10):407-7.e5. PubMed ID: 26561906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular disease prevention practices by U.S. Physicians for patients with diabetes.
    Meigs JB; Stafford RS
    J Gen Intern Med; 2000 Apr; 15(4):220-8. PubMed ID: 10759996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence to prescription guidelines and achievement of treatment goals among persons with coronary heart disease in Tromsø 7.
    Pedersen E; Garcia BH; Halvorsen KH; Eggen AE; Schirmer H; Waaseth M
    BMC Cardiovasc Disord; 2021 Jan; 21(1):44. PubMed ID: 33478404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilization of glucose, blood pressure, and lipid lowering medications among people with type II diabetes in the United States, 1999-2010.
    Wong HK; Ong KL; Cheung CL; Cheung BM
    Ann Epidemiol; 2014 Jul; 24(7):516-21.e1. PubMed ID: 24935464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing diabetes care regarding cardiovascular targets at general practice level: Direct@GP.
    Wens J; Gerard R; Vandenberghe H
    Prim Care Diabetes; 2011 Apr; 5(1):19-24. PubMed ID: 21030327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register.
    Karlsson SA; Franzén S; Svensson AM; Miftaraj M; Eliasson B; Andersson Sundell K
    BMC Health Serv Res; 2018 Nov; 18(1):900. PubMed ID: 30486824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants of appropriate lipid management in patients with ischaemic heart disease. Cracovian Program for Secondary Prevention of Ischaemic Heart Disease.
    Kawecka-Jaszcz K; Jankowski P; Pajak A
    Int J Cardiol; 2003 Sep; 91(1):15-23. PubMed ID: 12957725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perspectives on the role of exercise in the treatment of pediatric type 1 diabetes.
    Ilkowitz JR; Wu F; Chen Y; Gallagher MP
    Pediatr Diabetes; 2020 May; 21(3):466-472. PubMed ID: 31854483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States, part II: treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome.
    Bestermann W; Houston MC; Basile J; Egan B; Ferrario CM; Lackland D; Hawkins RG; Reed J; Rogers P; Wise D; Moore MA
    Am J Med Sci; 2005 Jun; 329(6):292-305. PubMed ID: 15958871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological management of modifiable cardiovascular risk factors (blood pressure and lipids) following diagnosis of myocardial infarction, stroke and diabetes: comparison between population-based studies in Russia and Norway.
    Cook S; Hopstock LA; Eggen AE; Bates K; Iakunchykova O; Kontsevaya A; McKee M; Schirmer H; Voevoda M; Kudryavtsev AV; Malyutina S; Leon DA
    BMC Cardiovasc Disord; 2020 May; 20(1):234. PubMed ID: 32430002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs.
    Stacy TA; Egger A
    J Manag Care Pharm; 2006; 12(9):745-51. PubMed ID: 17249907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.